Folate receptor-alpha (FOLR1) is highly expressed in ovarian cancer and correlates with poor clinical outcomes, making it an attractive target for adoptive cell therapy. Single-domain antibodies (V We generated a second-generation FOLR1-specific CAR incorporating a fully human V Both V Human FOLR1-V